96 related articles for article (PubMed ID: 10419050)
1. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.
Nemunaitis J; Fong T; Robbins JM; Edelman G; Edwards W; Paulson RS; Bruce J; Ognoskie N; Wynne D; Pike M; Kowal K; Merritt J; Ando D
Cancer Gene Ther; 1999; 6(4):322-30. PubMed ID: 10419050
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.
Nemunaitis J; Bohart C; Fong T; Meyer W; Edelman G; Paulson RS; Orr D; Jain V; O'Brien J; Kuhn J; Kowal KJ; Burkeholder S; Bruce J; Ognoskie N; Wynne D; Martineau D; Ando D
Cancer Gene Ther; 1998; 5(5):292-300. PubMed ID: 9824048
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
Khorana AA; Rosenblatt JD; Sahasrabudhe DM; Evans T; Ladrigan M; Marquis D; Rosell K; Whiteside T; Phillippe S; Acres B; Slos P; Squiban P; Ross M; Kendra K
Cancer Gene Ther; 2003 Apr; 10(4):251-9. PubMed ID: 12679797
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of retroviral vector-administered interferon-gamma (IFN-gamma) gene in metastatic melanoma.
Nemunaitis J; Buchanan A; Jolly DJ
Cancer Gene Ther; 2000 Oct; 7(10):1297-8. PubMed ID: 11059685
[No Abstract] [Full Text] [Related]
5. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
6. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
7. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
Shiau AL; Lin CY; Tzai TS; Wu CL
Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.
Nemunaitis J; Fong T; Burrows F; Bruce J; Peters G; Ognoskie N; Meyer W; Wynne D; Kerr R; Pippen J; Oldham F; Ando D
Hum Gene Ther; 1999 May; 10(8):1289-98. PubMed ID: 10365660
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
11. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer.
Singh S; Cunningham C; Buchanan A; Jolly DJ; Nemunaitis J
Mol Ther; 2001 Aug; 4(2):157-60. PubMed ID: 11482988
[TBL] [Abstract][Full Text] [Related]
12. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
[TBL] [Abstract][Full Text] [Related]
13. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
[TBL] [Abstract][Full Text] [Related]
14. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
[TBL] [Abstract][Full Text] [Related]
15. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
Rosenberg SA; Aebersold P; Cornetta K; Kasid A; Morgan RA; Moen R; Karson EM; Lotze MT; Yang JC; Topalian SL
N Engl J Med; 1990 Aug; 323(9):570-8. PubMed ID: 2381442
[TBL] [Abstract][Full Text] [Related]
17. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
19. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer.
Saleh M; Jonas NK; Wiegmans A; Stylli SS
Gene Ther; 2000 Oct; 7(20):1715-24. PubMed ID: 11083492
[TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.
Fujii S; Huang S; Fong TC; Ando D; Burrows F; Jolly DJ; Nemunaitis J; Hoon DS
Cancer Gene Ther; 2000 Sep; 7(9):1220-30. PubMed ID: 11023194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
